Xencor (XNCR) investor relations material

Strategic evolution and platform overview

• Focus on advancing differentiated molecules for severe diseases using XmAb Protein Engineering Platform, expanding from oncology into autoimmune indications.

• Emphasis on creating molecules with unique structural features for both cancer and autoimmune diseases, including bispecific T cell engagers and optimized monoclonal antibodies.

• Strategy centers on targeting unmet needs and achieving key clinical inflection points.

• Message of unique drug positioning and differentiation is resonating well in the market.

XmAb819 bispecific T cell engager program

• XmAb819 targets ENPP3, highly expressed in renal cell carcinoma and other solid tumors.

• Molecule designed for high avidity binding to tumor cells, minimizing off-target effects on healthy tissue.

• First ENPP3 T cell engager in the clinic, with dose escalation data to be presented at AACR NCI EORTC meeting in October.

• Preliminary data will focus on safety, anti-tumor activity, and initial response rates in advanced clear cell renal cell carcinoma.

• Uniformly high ENPP3 expression observed in late-line, heavily pretreated patients.

TL1A antibody and bispecific pipeline

• TL1A identified as a promising target for best-in-class antibody development, with current focus on ulcerative colitis and potential for broader indications.

• XmAb942, a long-acting TL1A antibody, entering phase 2b study (Zenith UC) in ulcerative colitis this quarter.

• Bispecific antibody combining TL1A and IL-23 targets planned for first-in-human studies in 2026, aiming for synergistic efficacy and safety.

• Modeling and design focus on achieving high drug exposure and 99% TL1A inhibition in the gut, supporting every-three-month dosing.

• Ongoing evaluation of additional indications, including skin and rheumatology diseases, as new data emerges.